Asunaprevir: Difference between revisions
Appearance
Content deleted Content added
update ref |
fix ref |
||
(5 intermediate revisions by 4 users not shown) | |||
Line 14: | Line 14: | ||
| PubChem = 16076883 |
| PubChem = 16076883 |
||
| ChemSpiderID = 17235944 |
| ChemSpiderID = 17235944 |
||
| ChEBI = 134723 |
|||
| DrugBank = DB11586 |
|||
| IUPHAR_ligand = 10882 |
|||
| ChEMBL = 2105735 |
| ChEMBL = 2105735 |
||
| KEGG = D10093 |
| KEGG = D10093 |
||
Line 45: | Line 48: | ||
| Legal_AU_comment = <ref>{{cite web | title=Prescription medicines: registration of new chemical entities in Australia, 2015 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia-2015 | access-date=10 April 2023}}</ref> |
| Legal_AU_comment = <ref>{{cite web | title=Prescription medicines: registration of new chemical entities in Australia, 2015 | website=Therapeutic Goods Administration (TGA) | date=21 June 2022 | url=https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia-2015 | access-date=10 April 2023}}</ref> |
||
| Legal_CA = Rx-only |
| Legal_CA = Rx-only |
||
| Legal_CA_comment = <ref>{{cite web | title=Health Canada New Drug Authorizations: 2016 Highlights | website=[[Health Canada]] | date=14 March 2017 | url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-canada-new-drug-authorizations-2016-highlights.html | access-date=7 April 2024}}</ref> |
|||
| Legal_CA_comment = |
|||
| Legal_NZ = |
| Legal_NZ = |
||
| Legal_NZ_comment = |
| Legal_NZ_comment = |
||
Line 60: | Line 63: | ||
| Pregnancy_AU_comment = |
| Pregnancy_AU_comment = |
||
| Dependence_liability = |
| Dependence_liability = |
||
| Addiction_liability = |
|||
| AdminRoutes = |
| AdminRoutes = |
||
| Bioavail = |
| Bioavail = |
||
Line 91: | Line 93: | ||
[[Category:Cyclopropanes]] |
[[Category:Cyclopropanes]] |
||
[[Category:CYP2D6 inhibitors]] |
[[Category:CYP2D6 inhibitors]] |
||
[[Category:Experimental drugs]] |
[[Category:Experimental antiviral drugs]] |
||
[[Category:Isoquinolines]] |
[[Category:Isoquinolines]] |
||
[[Category:NS3/4A protease inhibitors]] |
[[Category:NS3/4A protease inhibitors]] |
||
Line 97: | Line 99: | ||
[[Category:Sulfonamides]] |
[[Category:Sulfonamides]] |
||
[[Category:Tert-butyl compounds]] |
[[Category:Tert-butyl compounds]] |
||
[[Category:Methoxy compounds]] |
|||
Revision as of 05:20, 7 April 2024
Names | |
---|---|
IUPAC name
3-Methyl-N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-valyl-(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-vinylcyclopropyl}-L-prolinamide
| |
Systematic IUPAC name
tert-Butyl {(2S)-1-[(32S,34R,61R,62S)-17-chloro-62-ethenyl-14-methoxy-4,7,9,9-tetraoxo-2-oxa-9λ6-thia-5,8-diaza-1(1)-isoquinolina-3(4,2)-pyrrolidina-6(1,1),10(1)-dicyclopropadecaphan-31-yl]-3,3-dimethyl-1-oxobutan-2-yl}carbamate | |
Other names
BMS-650032
| |
Identifiers | |
3D model (JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard | 100.206.482 |
KEGG | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C35H46ClN5O9S | |
Molar mass | 748.29 g·mol−1 |
Pharmacology | |
J05AP06 (WHO) | |
Legal status | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Asunaprevir (formerly BMS-650032, brand name in Japan and Russia[3] Sunvepra) is an experimental drug candidate for the treatment of hepatitis C. It was undergoing development by Bristol-Myers Squibb and has completed Phase III clinical trials in 2013.[4]
Asunaprevir is an inhibitor of the hepatitis C virus enzyme serine protease NS3.[5] Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.[6][7][8]
References
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
- ^ "Sunvepra (asunaprevir) soft gelatin capsules 100 mg. Registration certificate". State Register of Medicines (in Russian). Retrieved 26 August 2015.
- ^ "A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients". ClinicalTrials.gov. 23 September 2015.
- ^ C. Reviriego (2012). "Asunaprevir. HCV serine protein NS3 inhibitor, Treatment of hepatitis C virus". Drugs of the Future. 37 (4): 247–254. doi:10.1358/dof.2012.037.04.1789350.
- ^ Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. (January 2012). "Preliminary study of two antiviral agents for hepatitis C genotype 1". The New England Journal of Medicine. 366 (3): 216–24. doi:10.1056/NEJMoa1104430. PMID 22256805.
- ^ "Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study". Bloomberg. 19 April 2012.
- ^ AASLD: Daclatasvir plus Asunaprevir Rapidly Suppresses HCV in Prior Null Responders Archived 2015-02-08 at the Wayback Machine. Highleyman, L. HIVandHepatitis.com. 8 November 2011.